肿瘤药学2025，Vol.15Issue(4)：462-469,8.DOI:10.3969/j.issn.2095-1264.2025.04.04
乳腺癌靶向治疗新挑战:抗体偶联药物相关心脏毒性的发生机制与临床管理
Emerging challenge in targeted therapy for breast cancer:mechanisms and clinical management of antibody-drug conjugate-associated cardiotoxicity
摘要
Abstract
Antibody-drug conjugates(ADC)have significantly improved survival outcomes in breast cancer patients.However,ADC-associated cardiotoxicity has emerged as a critical limiting factor impacting treatment benefit.Multiple FDA-approved ADC agents are currently available for breast cancer,including trastuzumab emtansine(T-DM1),trastuzum-ab deruxtecan(T-DXd),sacituzumab govitecan(SG),sacituzumab tirumotecan(SKB264),etc.This article systematically re-views the mechanisms of cardiotoxicity,clinical manifestations,risk assessment,monitoring strategies,and management ap-proaches for ADC therapies in breast cancer.We aim to guide the safe and effective clinical application of ADC drugs in breast cancer.关键词
抗体药物偶联物/乳腺癌/心脏毒性Key words
Antibody-drug conjugate/Breast cancer/Cardiotoxicity分类
医药卫生引用本文复制引用
姜翠,孙涛,李晓睿,蒋雷,鄂颖,马艺文,苗磊,王媛,王家行,刘军..乳腺癌靶向治疗新挑战:抗体偶联药物相关心脏毒性的发生机制与临床管理[J].肿瘤药学,2025,15(4):462-469,8.基金项目
辽宁省自然科学基金重点研发项目(2024JH2/102500058) （2024JH2/102500058）
辽宁省自然科学基金博士科研启动基金计划项目(2023-BS-042) （2023-BS-042）
沈阳市科学技术计划公共卫生研发专项(22-321-31-04). （22-321-31-04）
